ReviewCancers2022
Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Facilitators and barriers of lung cancer screening participation: umbrella and systematic review of the global evidence.BMC public health · 2025Pooled it
- Utilisation of endocrine therapy for cancer in Indigenous peoples: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- Mapping population-based cancer registries in Europe: coverage, data availability, and capacity for real-world data generation.ESMO real world data and digital oncology · 2026Article
- Alveolar Epithelial Cell Dysfunction in Acute Respiratory Distress Syndrome: Mechanistic Insights and Targeted Interventions.Biomedicines · 2025Review
- Optimizing Patient Registries for Regulatory Decision Making - Key Learnings From an HMA/EMA Multistakeholder Workshop.Clinical pharmacology and therapeutics · 2025Review
- Factors associated with diagnostic and treatment intervals in colorectal cancer: A linked data study.International journal of cancer · 2025Article
- Neoadjuvant Chemotherapy With Chemoradiotherapy for Patients With Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma-Retrospective Review From a Tertiary Care Hospital.Asia-Pacific journal of clinical oncology · 2025Article
- Radiotherapy and time to initial treatment following a cancer diagnosis among First Nations Australians: results from a population-based analysis.Archives of public health = Archives belges de sante publique · 2025Article
- Stronger together; evaluating consumers and researchers working in partnership.Research involvement and engagement · 2025Article
- Completeness Evaluation of Adult-Population-Based Cancer Registries: A Systematic Review.Cancers · 2025Review
- Cancer survivorship in low- and middle-income countries: challenges, needs, and emerging support strategies.Frontiers in public health · 2025Review
- Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, multicentre, real-world analysis.ESMO real world data and digital oncology · 2024Article
- Co-designing a personalised care plan for patients with rectal cancer: reflections and practical learnings.Research involvement and engagement · 2024Article
- Quality assessment of a rural population-based cancer registry (PBCR) at Ratnagiri, Maharashtra, India for the years 2017-18.Ecancermedicalscience · 2024Article
- The value of real world evidence and pragmatic trials in advanced prostate cancer- insights from the electronic Prostate Cancer Australian and Asian Database.Frontiers in oncology · 2024Article
- Highlighting the value of Alzheimer's disease-focused registries: lessons learned from cancer surveillance.Frontiers in aging · 2023Article
- Timeliness of Care and Treatment Patterns for Pancreatic Cancer in Victoria, Australia: Comparison With Optimal Care Pathways Targets.ANZ journal of surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional cancer registries have often been siloed efforts, established by single groups with limited objectives. There is the potential for registry data to support a broad range of research, audit and education initiatives. Here, we describe the establishment of a series of comprehensive cancer registries across the spectrum of common solid cancers. The experience and learnings of each registry team as they develop, implement and then use collected data for a range of purposes, that informs the conduct and output of other registries in a virtuous cycle. Each registry is multi-site, multi-disciplinary and aims to collect data of maximal interest and value to a broad range of enquiry, which would be accessible to any researcher with a high-quality proposal. Lessons learnt include the need for careful and continuous curation of data fields, with regular database updates, and the need for a continued focus on data quality. The registry data as a standalone resource has supported numerous projects, but linkage with external datasets with patients in common has enhanced the audit and research potential. Multiple projects have linked registry data with matched tissue specimens to support prognostic and predictive biomarker studies, both validation and discovery. Registry-based biomarker trials have been successfully supported, generating novel and practice-changing data. Registry-based clinical trials, particularly randomised studies exploring the optimal use of available therapy options are now complementing the research conducted in traditional clinical trials. More recent projects supported by the registries include health economic studies, personalised patient education material, and increased consumer engagement, including consumer entered data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.